

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Seymour Fein

Application No.: 10/706,100

Confirmation No.: 7710

Filed: November 12, 2003

Art Unit: 1654

For: Pharmaceutical compositions including low
dosages of desmopressin

Examiner: A. D. Kosar

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed after the mailing date of a Final Office Action or Notice of Allowance, whichever occurred first, but on or before payment of the Issue Fee (37 CFR 1.97(d)). Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered.

I hereby certify, pursuant to 37 CFR 1.97(e)(2), that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this

Information Disclosure Statement. Applicant notes that the publication listed on the attached PTO/SB/08 was cited in the Fjellestad-Poulson thesis upon which certain of the outstanding claim rejections rely. Applicant has now obtained a copy of the latest publication and submits it to the Office for consideration.

Applicant submits herewith a copy of the non-patent literature in accordance with 37 CFR 1.98(a)(2).

Please charge our Deposit Account No. 07-1700 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 07-1700, under Order No. SER-001.

Dated: May 8, 2009

Respectfully submitted,

Electronic signature: /Brian A. Fairchild/

Brian A. Fairchild

Registration No.: 48,645

GOODWIN PROCTER LLP

Exchange Place

Boston, Massachusetts 02109

(617) 570-1000

Attorney for Applicant